Enanta Pharmaceuticals Inc

ENTA is in a Stage 2 advancement within a longer-term downtrend. Price has executed a Lockout Rally, reclaiming short- and medium-term EMAs on expanding volume and signaling urgent forced buying. Despite overbought RSI and elevated options interest, the Lockout Rally override supports continued execution readiness. Medium-term bullish permission remains intact, and a Buy Now posture is advised for continuation participation above the mid-June breakout zone.

• ↑SPRINT trial data for EDP-235 shows significant symptom improvement
• ↑$300M cash balance funds operations through mid-2027 despite Q2 $31.2M loss
• ↓Q2 revenue fell 4% YoY to $17.1M as AbbVie royalties decline